Payment overview · 2025
General Payments
$407.34
24 reported records · 9 companies
Healthcare provider profile · identity verified
Melissa D Johnson, DO
Allopathic & Osteopathic Physicians|Family Medicine · FENTON, MO · NPI 1548284896
Verified facts
What the public records show
CMS Open Payments records show Melissa D Johnson, DO received $407.34 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 43.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Prolia, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.23 | 43.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.88 | 11.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.67 | 10.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.60 | 9.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.60 | 8.2% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $19.39 | 4.8% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $19.16 | 4.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.11 | 4.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.70 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $407.34 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.48 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.79 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.88 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.67 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.80 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | ARRAY BIOPHARMA INC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | ARRAY BIOPHARMA INC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 61 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 78 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
61 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 166 |
| Lisinopril | Lisinopril | 450 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 429 | 134 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 400 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 91 |
| Losartan Potassium | Losartan Potassium | 306 | 89 |
| Alprazolam | Alprazolam | 236 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 61 |
| Metformin Hcl | Metformin Hcl | 198 | 59 |
| Meloxicam | Meloxicam | 179 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 53 |
| Tramadol Hcl | Tramadol Hcl | 168 | 59 |
| Omeprazole | Omeprazole | 167 | 49 |
| Gabapentin | Gabapentin | 144 | 43 |
| Trazodone Hcl | Trazodone Hcl | 138 | 41 |
| Alendronate Sodium | Alendronate Sodium | 129 | 49 |
| Ozempic | Semaglutide | 129 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 41 |
| Bupropion Xl | Bupropion Hcl | 117 | 34 |
| Montelukast Sodium | Montelukast Sodium | 115 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 39 |
| Sertraline Hcl | Sertraline Hcl | 111 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 19 |
| Furosemide | Furosemide | 80 | 33 |
| Glipizide Er | Glipizide | 80 | 25 |
| Lorazepam | Lorazepam | 79 | 20 |
| Eliquis | Apixaban | 78 | 20 |
| Celecoxib | Celecoxib | 75 | 20 |
| Potassium Chloride | Potassium Chloride | 70 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 45 |
| Amoxicillin | Amoxicillin | 65 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 21 |
| Allopurinol | Allopurinol | 62 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 61 | 60 |
| Famotidine | Famotidine | 55 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Simvastatin | Simvastatin | 54 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 17 |
| Glipizide | Glipizide | 50 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 18 |
| Donepezil Hcl | Donepezil Hcl | 47 | 17 |
| Carvedilol | Carvedilol | 46 | 15 |
| Memantine Hcl | Memantine Hcl | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Temazepam | Temazepam | 46 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 38 |
| Clonazepam | Clonazepam | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Metformin Hcl Er | Metformin Hcl | 43 | 15 |
| Prednisone | Prednisone | 42 | 30 |
| Valacyclovir | Valacyclovir Hcl | 39 | 21 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 13 |
| Diazepam | Diazepam | 34 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Valsartan | Valsartan | 33 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Benzonatate | Benzonatate | 25 | 16 |
| Finasteride | Finasteride | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Atenolol | Atenolol | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Nystatin | Nystatin | 20 | 14 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $407.34 · 24 records | ABBVIE INC. | AIRSUPRA, AREXVY, BRAFTOVI, ELIQUIS, EVENITY, ImmunoCAP, MOUNJARO, PROLIA, QULIPTA, SHINGRIX, TALZENNA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, XTANDI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error